AAM Questions FDA’s Product Identifiers in Supply Chain Guidance

Generic drugmakers urged the FDA to allow for more flexibility in draft guidance on product identifiers under the Drug Supply Chain Security Act (DSCSA).
Source: Drug GMP Report